Non-specific double-stranded DNA (dsDNA)

Non-specific double-stranded DNA (dsDNA) serves as a foundational therapeutic target, particularly in oncology where it is the primary site of action for many traditional cytotoxic chemotherapies (1.1.1, 1.1.3). Unlike precision therapies that target specific genetic mutations, these agents interact with the DNA duplex regardless of its sequence, typically through mechanisms such as intercalation, covalent alkylation, or the induction of strand breaks (1.2.1, 1.2.4). By disrupting the structural integrity of genomic DNA, these drugs effectively inhibit essential cellular processes including replication and transcription, thereby triggering apoptosis in rapidly proliferating cells (1.2.1, 1.3.3). Beyond its role as a drug target in cancer, dsDNA is a critical autoantigen in systemic lupus erythematosus (SLE), where the presence of anti-dsDNA antibodies is a hallmark of disease activity and a driver of organ damage, particularly lupus nephritis (1.4.3, 1.4.5). While highly effective at killing malignant cells, the non-specific nature of these interactions leads to significant therapeutic challenges, including systemic toxicities such as myelosuppression and an increased risk of secondary malignancies due to the mutagenic potential of DNA-damaging agents (1.2.1, 1.3.3). Consequently, modern research often focuses on identifying biomarkers, such as SLFN11 expression, to better stratify patients who will benefit from these broad-spectrum DNA-targeting strategies (1.1.1, 1.1.3).

Other names

Double-stranded DNAGenomic DNADNA duplexdsDNADeoxyribonucleic acid

Drugs interact with dsDNA through non-specific mechanisms such as intercalation between base pairs, covalent alkylation (forming intra- and inter-strand cross-links), and oxidative strand cleavage, which collectively inhibit DNA replication, transcription, and topoisomerase activity, ultimately triggering apoptosis (1.2.1, 1.2.4, 1.4.2).